← All countries · Western Pacific
91%
MCV1
2025 · WHO/UNICEF estimate
92%
DTP3
2025 · WHO/UNICEF estimate
93%
IPV complete
2025 · WHO/UNICEF estimate
94%
HepB3
2025 · WHO/UNICEF estimate
181
Measles cases
2025 reported
25,277
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 0%1996 · Administrative (country-reported) | 0% | too few points | D · poor |
| DTP1First dose of diphtheria-tetanus-pertussis | 92%2025 · WHO/UNICEF estimate | — | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 92%2025 · WHO/UNICEF estimate | 91.7% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 93%2025 · WHO/UNICEF estimate | — | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 93%2025 · WHO/UNICEF estimate | 93.2% | C · weak | |
| MCV1First dose of measles-containing vaccine | 91%2025 · WHO/UNICEF estimate | — | A · strong | |
| MCV2Second dose of measles-containing vaccine | 91%2025 · WHO/UNICEF estimate | 91.0% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 91%2025 · WHO/UNICEF estimate | — | B · good | |
| HepB3Third dose of hepatitis B vaccine | 94%2025 · WHO/UNICEF estimate | 93.9% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 65%2025 · WHO/UNICEF estimate | 65.0% | C · weak | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 92%2025 · WHO/UNICEF estimate | 91.7% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 94%2025 · WHO/UNICEF estimate | 93.6% | A · strong | |
| RotaCRotavirus vaccine, complete series | 68%2025 · WHO/UNICEF estimate | 67.7% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 75%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 75%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 73%2025 · WHO/UNICEF estimate | — | B · good |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 1812025 | 6.7per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 22025 | 0.1per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 1712025 | 6.3per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 25,2772025 | 937.1per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 262025 | 1per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 12025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02021 | 0per 1,000 live births | D · poor | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 92025 | 0.3per 1,000,000 total population | B · good | |
| Invasive meningococcal disease all countries · vaccine evidence | 1172025 | 4.3per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 2302025 | 8.5per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (42 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTAPDTaP (acellular) vaccine | 4 | M18 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y4 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M18 | Risk group(s) · SUBNATIONAL | Aboriginal and Torres Strait Islander people in Queensland, Northern Territory, Western Australia and South Australia |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | Y4 | Risk group(s) · SUBNATIONAL | Aboriginal and Torres Strait Islander people in Queensland, Northern Territory, Western Australia and South Australia |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | >=Y19 | Risk group(s) | Refugee and humanitarian entrants |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 4 | M18 | General/routine | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12-Y13 | HPV administered to females and males | Single dose, school grade 7 or age equivalent, all genders |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons 65 years+ |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | ||
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-M59 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MEN_ACYW_135PSMeningococcal ACYW polysaccharide vaccine | 1 | M12 | General/routine | |
| MEN_ACYW_135PSMeningococcal ACYW polysaccharide vaccine | 2 | Y14-Y16 | General/routine | |
| MEN_BMeningococcal B vaccine | 1 | M2 | Risk group(s) · SUBNATIONAL | Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions. |
| MEN_BMeningococcal B vaccine | 2 | M4 | Risk group(s) · SUBNATIONAL | Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions. |
| MEN_BMeningococcal B vaccine | 3 | M6 | Risk group(s) · SUBNATIONAL | Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions. |
| MEN_BMeningococcal B vaccine | 4 | M12 | Risk group(s) · SUBNATIONAL | Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions. |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | M18 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | >=Y70 | Adults | given to adults 70 years and over (not including Aboriginal and Torres Strait Islander adults). |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | <Y18 | Risk group(s) | All children medically at risk |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M4 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M12 | General/routine | M12 dose may be 4th dose if M6 dose is administered to risk groups or for Aboriginal and Torres Strait Islander children |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M6 | Risk group(s) | M6 given to all Aboriginal and Torres Strait Islander Children and all children with medical risk conditions. Given to all persons <Y18 with medical risk conditions |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y50 | Adults | Aboriginal and Torres Strait Islander Adults |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Pregnant women | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y12-Y13 | General/routine | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y50 | Adults | >=65 for all Adults. >=50 for Aboriginal and Torres Strait Islander Adults |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.